We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Regeneron, which was thinking its blockbuster eye drug Eylea would extend its market dominance with a new, more convenient 12-week dosing schedule for some patients, is having to think twice. The FDA has interrupted those plans with delivery of a CRL.